Myriad GeneticsSTU:MYD +4.86%53 Pretax Margin % is -17.02% as of Mar. 2026. GuruFocus rates STU:MYD with a GF Score™ of 53/100 and a GF Value™ of €13.14 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, Myriad Genetics ranks worse than 75.25% on this metric.
The historical rank and industry rank for Myriad Genetics's Pretax Margin % or its related term are showing as below:
STU:MYD'
s Pretax Margin % Range Over the Past 10 Years
Min: -48.23 Med: -14.74 Max: 21.07
Current: -48.23
STU:MYD's Pretax Margin % is ranked worse than 75.25% of 202
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.565
vs STU:MYD: -48.23
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Myriad Genetics Pretax Margin % Related Terms
Myriad Genetics Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Myriad Genetics's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:MYD vs FLGT, CSTL, BDSX: Pretax Margin % Comparison
For the Diagnostics & Research subindustry, Myriad Genetics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Myriad Genetics Pretax Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Myriad Genetics's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Myriad Genetics (STU:MYD) has a Pretax Margin % of -17.02% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Myriad Genetics and its competitors. According to the industry distribution chart, Myriad Genetics ranks #152 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 75.2%.
Is Myriad Genetics' Pretax Margin % too high?
Myriad Genetics' current Pretax Margin % is -17.02%. Based on the distribution chart, Myriad Genetics ranks #152 out of 202 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Myriad Genetics has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Myriad Genetics' Pretax Margin % compare to FLGT and CSTL?
According to the Medical Diagnostics & Research industry distribution chart, Myriad Genetics ranks #152 out of 202 companies for Pretax Margin %. This places Myriad Genetics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Diagnostics & Research company?
A good Pretax Margin % depends on the Medical Diagnostics & Research industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Myriad Genetics and its competitors. Myriad Genetics's current Pretax Margin % is -17.02%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Myriad Genetics stock overvalued right now?
Based on GuruFocus' analysis, Myriad Genetics (STU:MYD) is currently considered Possible Value Trap. The stock's GF Value™ is €13.14, compared to a current price of €5.20 — trading 60.4% below its estimated fair value. The current Pretax Margin % is -17.02%. Myriad Genetics' overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Myriad Genetics (STU:MYD), the current Pretax Margin % is -17.02% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Myriad Genetics (STU:MYD) Overvalued in 2026?
Based on GuruFocus' analysis, Myriad Genetics stock appears to be undervalued.
The current stock price of €5.20 is trading 60.4% below its estimated GF Value™ of €13.14.
GuruFocus considers Myriad Genetics to be Possible Value Trap.
Key valuation signals for STU:MYD:
Pretax Margin %: -17.02%
GF Value™: €13.14 vs. price of €5.20 (60.4% below fair value)
No single metric tells the full story. See the STU:MYD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
53GF Score
Get the complete analysis for STU:MYD
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:MYD has been successfully added to your 
